企業プロフィール · Healthcare

Laboratory Corporation of America Holdings

LH · 米国株
取引所
米国株
国 / 地域
USA
上場日
1990年3月29日
従業員数
71,000
公式サイト
www.labcorp.com
現在値
$255.82
リアルタイム · 2026年6月18日
妥当買付価格
≤ $210
安全マージンの起点
ベイリー成長スコア
44/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 $255.82 リアルタイム · 妥当な本源的価値レンジ内

総合バリュエーションレンジ · 保守的 $145–$200 / 妥当 $220–$280 / 楽観的 $280–$326。$255.82 時点で 妥当な本源的価値レンジ内。

レポート公開時 $262.75(2026年5月29日)

この銘柄のレポートはお使いの言語でまだありません。

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North

時価総額$213.17億
売上高(TTM)$141.44億
EBITDA$22.53億
純利益率6.66%
ROE11.05%
PER (TTM)23.05
予想PER14.77
PEG1.12
EPS$11.28
配当利回り1.09%
52週レンジ$239.28 – $291.40
アナリスト目標株価$310.12
アナリスト評価4.5 / 5

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。